GSK stock advances pipeline focus at Guggenheim conference

Published on 11/09/2026 at 18:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock enters investor week with a sharper focus on long-acting biologics and combination therapy. Respiratory and liver programs lead the agenda.

Pipeline Takes Center Stage

GSK outlined a research strategy built around long-acting biologics, combination therapy and earlier use of human data.
Felcorekibart is moving toward six Phase III starts across asthma, nasal polyps and COPD.
The company plans a Phase III start for its IL-33 COPD program and is testing a TSLP and IL-33 combination.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK used the Guggenheim Healthcare Innovation Conference on Monday, November 9, 2026, to sharpen its pipeline message around long-acting biologics, combination therapy and earlier use of human data in drug development. The company presented respiratory and liver programs as important areas for future growth.

According to Investing.com, GSK is using a reverse-translation approach that starts with clinical questions and patient characteristics before selecting development paths. Management highlighted chronic obstructive pulmonary disease as an underappreciated opportunity.

Respiratory Pipeline Gains Momentum

GSK's long-acting TSLP candidate felcorekibart is advancing through the PERSIST program. The company said the program is moving toward six simultaneous Phase III starts across asthma, chronic rhinosinusitis with nasal polyps and COPD.

GSK also plans a Phase III start for its IL-33 program in COPD. The program is designed as a cardiopulmonary outcomes study, while a separate Phase II program in non-CF bronchiectasis is intended to expand the potential use of the mechanism.

Combination therapy is another part of the development strategy. GSK has started a study testing co-administration of two monospecific medicines targeting TSLP and IL-33 in COPD patients. The aim is to establish whether the two mechanisms provide additive or synergistic effects before a possible bispecific approach.